Jeff Steinhoff, MD
Cardiovascular Disease · Largo, FLNPI 1811959869
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 52 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 26.8% of the total. Reporting peaked in 2019 at $22,207 and has fallen 86.7% since, to $2,952 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 650 payments — averaging $60.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$11K
- Amgen$7K
- Abbott$4K
- Regeneron Healthcare Solutions, Inc.$4K
- Boston Scientific$2K
- Medtronic$1K
- plus $10K from 46 others
Across 4 payments — averaging $5582.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$11K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
- Novartis$3K
What the payments were for
- Speaking & faculty fees$18,45747%
- Travel & lodging$1,7554%
- Food & beverage$19,36049%
- Education$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRALUENT$13,645
- Repatha$5,600
- Mitra Clip system$652
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$556
- TRICLIP$429
- XARELTO$370
- AccuCinch$316
- CoreValve Evolut$312
- Auryon Laser System 100-120 Vac$296
- COREVALVE EVOLUT R$258
- LUX-Dx Insertable Cardiac Monitor$227
- NAVITOR$215
- TactiCath Quartz CFA Catheter$166
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$160
- ASSURITY$154
- SYMPLICITY G3$153
- OPTICROSS$150
- AFX$144
- Impella$139
- RotarexS 6 F x 135 cm$137
How this compares
$39,634 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $213,286 |
| XareltoRivaroxaban | 151 | $175,623 |
| EntrestoSacubitril/Valsartan | 135 | $151,635 |
| Repatha SureclickEvolocumab | 97 | $112,412 |
| FarxigaDapagliflozin Propanediol | 79 | $95,014 |
| JardianceEmpagliflozin | 74 | $80,494 |
| VascepaIcosapent Ethyl | 38 | $31,021 |
| BrilintaTicagrelor | 27 | $28,004 |
| Repatha SyringeEvolocumab | 11 | $12,181 |
| Atorvastatin Calcium | 813 | $8,374 |
| Praluent PenAlirocumab | 14 | $6,954 |
| Metoprolol Succinate | 302 | $4,645 |
| ClopidogrelClopidogrel Bisulfate | 355 | $4,192 |
| Ezetimibe | 228 | $3,790 |
| Rosuvastatin Calcium | 268 | $3,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $721 | $213,286178 claims |
| Johnson & JohnsonXarelto | $1,311 | $175,623151 claims |
| NovartisEntresto | $985 | $151,635135 claims |
| AstraZenecaFarxiga, Brilinta | $733 | $123,018106 claims |
| Boehringer IngelheimJardiance | $507 | $80,49474 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Largo
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.